Search This Blog

Wednesday, February 1, 2023

Ivermectin: Could Population-Wide Distribution Have Prevented Recent China COVID Outbreak?

 by Dr. Sean Lin and Mingjia Jacky Guan via The Epoch Times (emphasis ours),

China’s state-run medicare program recently failed to reach an agreement with Pfizer to import more Paxlovid, claiming the COVID-19 treatment drug is too expensive. This is despite the drug being offered to the state at a reduced rate in comparison with that offered to other developed countries. Lack of Paxlovid will leave only Azvudine, an anti-HIV drug the Chinese communist regime rushed through development and re-branded as an anti-COVID drug, as a treatment option.

Given the recent explosive spread of COVID and the resulting skyrocketing rates of hospitalization, finding viable treatment options is paramount.

Ivermectin in India and Peru

When the Delta variant broke out in 2021 across India, many states offered ivermectin population-wide. The efficacy of ivermectin in treating early and mild COVID-19 infections was confirmed in large states such as Uttar Pradesh—home to 241 million residents—where the use of the prophylactic dramatically reduced both the infection rate and the death toll.

Data from a study comparing the efficacy of ivermectin in frontline health care workers. (The Epoch Times)

Even among frontline health care workers, ivermectin proved to be an effective prophylactic against COVID-19. One study with 3,532 frontline health care workers from the All India Institute of Medical Sciences Bhubaneswar found that two doses of oral ivermectin (300 μg/kg given 72 hours apart) as chemoprophylaxis among health care workers reduced the risk of COVID-19 infection by 83 percent in the following month.

In Peru, mass ivermectin treatments were conducted through a broad-scale effort called Mega-Operación Tayta, or MOT for short. Operation MOT was led by the Peruvian army and involved 10 states, where the excess death rate saw a sharp decline with an average of 74 percent over 30 days. In 14 states where ivermectin was administered locally, the mean reduction in excess deaths over 30 days compared with deaths was 53 percent.

Lima, the capital of Peru, where the distribution of ivermectin was restricted, saw only a 25 percent reduction in excess deaths. The findings of researchers, detailed in the diagram below, show infection numbers, deaths, and fatalities across Peruvian states which implemented ivermectin (blue) and those which did not (red). The conclusion is that a reduction in deaths correlated with the distribution of ivermectin with a statistically significant p-value of less than 0.002.

COVID-19 data from Peru’s 2021 Delta outbreak comparing states that dispensed ivermectin (green) and those that did not (blue). (The Epoch Times)

Ivermectin–The Wonder Drug

Ivermectin was discovered in Japan during the late 70s as a derivative of Avermectin, produced from a single organism isolated at the Kitasato Institute in Tokyo. Since then, ivermectin has played an immeasurable role in improving the lives of billions with its humble beginnings as an anti-parasitic drug.

Ivermectin, approved by the U.S. Food and Drug Administration and deployed worldwide since 1987, has made major inroads against two devastating tropical diseases—onchocerciasis and lymphatic filariasis. In addition, some topical forms of ivermectin are approved to treat external parasites like head lice and skin conditions such as rosacea.

Ivermectin is potentially effective against a host of viruses. (The Epoch Times)

In addition to its anti-parasitic effects, a 2022 study published in the European Journal of Medicinal Chemistry Reports found that ivermectin has a strong potency at low concentrations against many DNA and RNA viruses, including HIV-1, yellow fever, malaria, West Nile virus, Zika, dengue fever, etc.

According to the study, ivermectin has an amazing inhibitory effect across multiple species and can interrupt motility and reproduction in both arthropods (such as insects) and nematodes (such as roundworms). This explains why ivermectin is prescribed for parasite infections, and also sheds light on its potential as a prophylactic against vector-borne diseases. In insects and other arthropods specifically, it can interrupt the transmission of disease.

Ivermectin’s Potential Mechanisms Against COVID

SARS-CoV-2 is a virus that takes over host cells to multiply in the body. To enter the host cells, the virus binds to the ACE-2 receptor on the surface of cells which grants them entry. Ivermectin prevents the bonding process by interfering with the virus’s spike proteins—this is the same mechanism the vaccines use.

If the virus slips past the cell membrane, its top priority is to infiltrate the brain of the cell—the DNA-containing nucleus—to start mass-producing itself. SARS-CoV-2 latches itself onto a special class of transport proteins called IMPs that have enough security clearance to enter the nucleus. In the case of a viral infection, ivermectin binds to these transport proteins and halts the interaction.

Ivermectin inhibiting intracellular transport and viral production. (The Epoch Times)

Ivermectin also inhibits the nuclear transport mechanism mediated by the KPNA-1 protein, which has a similar effect when compared with IMPs. Both proteins can enter the nucleus and ivermectin can effectively stop the virus from getting to the nucleus. In the event that the virus does manage to invade the nucleus—ivermectin also has a backup plan.

For example, when the virus has taken over and initialized self-replication, it does so through a protein called RdRp, which is at the centerpiece of viral replication—and is directly inhibited by ivermectin with very high efficacy.

Ivermectin Could Reduce Severe Lung Damage in COVID Patients

Once COVID-19 reaches later stages, it may require intensive care for recovery. For example, white lung syndrome (a hallmark symptom of acute respiratory distress syndrome) now occurring in severe COVID infections in China, is a sign that the virus has deeply infected the lungs and may have caused cytokine storms (a severe immune reaction in the body) in patients.

Other complications that arise from COVID-19 involving the lungs are conditions such as pulmonary fibrosis and hypoxia. Hypoxia occurs when the virus infects lung tissue to the extent that the alveoli, tiny sacs of air at the end of lung branches responsible for oxygen exchange, become scarred causing a severe loss of oxygen in the body.

Cytokines and chemokines are responsible for inflammation, a natural immune system response to foreign invaders. However, a large number of cytokines released into the body all at once can cause a “cytokine storm,” wherein the body is flooded with armies of white blood cells that harm the body.

A cytokine storm can be triggered through the TLR-4 pathway by the virus. The same pathway also triggers the release of nitric oxide, causing fluid leaks, dilating blood vessels, or even sepsis and fluid buildup in the lungs.

https://www.zerohedge.com/political/ivermectin-could-population-wide-distribution-have-prevented-chinas-recent-mass-covid

Pfizer forecasts big drop in revenue after record $100M COVID-led haul

 Pfizer on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and treatment for 2023, intensifying investor concerns over demand for the products as governments cut orders and work through inventories.

Chief Executive Albert Bourla said that 2023 should be a “transition year” for Pfizer’s COVID products, before potentially returning to growth in 2024.

Pfizer’s total annual sales crossed the $100 billion mark for the first time in 2022, driven by the more than $56 billion in sales of its COVID-19 vaccine and Paxlovid antiviral treatment. It expects total 2023 revenue of $67 billion to $71 billion.

“We are building on a significant capital position that we know how to deploy to create growth,” Bourla told analysts and investors on conference call. “We are building an R&D engine that is more productive than ever.”

The company launched five new products last year and hopes to introduce as many as 14 more over the next year and a half, including a vaccine for respiratory syncytial virus (RSV) and an mRNA flu vaccine.

Pfizer CEO Albert Bourla
Pfizer CEO Albert Bourla said that 2023 should be a “transition year” for Pfizer’s COVID products, before potentially returning to growth in 2024.
REUTERS

Pfizer shares rose 1.4% to $44.16. The stock had tumbled 15% this month, through Monday’s close.

Citi analyst Andrew Baum said the company is struggling to escape its dependence on COVID drugs.

“We see little here to change our cautious view on Pfizer’s ex-COVID business,” Baum said in a research note.

The decline in COVID-related revenue is not the only headwind Pfizer is facing.

The US drugmaker will lose patent protections for some big-selling drugs after 2025, including cancer treatment Ibrance and arthritis drug Xeljanz, and has said it expects to lose $17 billion in annual sales between 2025 and 2030 due to patent expirations.

Pfizer has turned to acquisitions such as its $5.4 billion buyout of Global Blood Therapeutics and its $11.6 billion purchase of migraine drugmaker Biohaven to bolster its pipeline of future products.

A vial of the Pfizer-BioNTech COVID-19 vaccine.
Pfizer forecast 2023 sales of $13.5 billion for its COVID-19 vaccine, below analysts’ estimates of $14.4 billion.
AFP via Getty Images

Citi’s Baum said he expects Pfizer will use the spike in revenue from its COVID products to “intensify and upscale” its efforts to buy other companies or new products to fill its pipeline.

Excluding COVID-related sales, Pfizer expects 2023 revenue to grow 7% to 9%.

Pfizer developed its COVID-19 vaccine with German partner BioNTech, and the companies split the profits. Pfizer forecast 2023 sales of $13.5 billion for their vaccine, below analysts’ estimates of $14.4 billion, and projected $8 billion in Paxlovid sales, short of Wall Street’s expectation of $10.33 billion.

Bourla said the company expects to start selling its COVID vaccine Comirnaty through commercial channels in the United States in the second half of 2023, rather than selling the shots directly to the government. After that transition, the company hopes to roughly quadruple the US price of the vaccine.

Analysts and investors have been looking for clarity on China demand for Paxlovid, where the drug is only covered by the country’s broad healthcare insurance plan until late March.

Pfizer said its current 2023 forecast for sales does not assume any revenue from China after April 1, but Bourla said the company expects to offer Paxlovid in the private market there thereafter.

“There is still an opportunity for a market in China which could be meaningful” outside of the country’s main insurance channels, said BMO Analyst Evan Seigerman.

https://nypost.com/2023/01/31/pfizer-forecasts-big-drop-in-revenue-after-record-100m-covid-led-haul/

SUNY makes new racial equity class mandatory for graduation at all schools

 The 64-campus SUNY college system is turning into the Woke University of New York — ordering incoming freshman at all of its colleges they will have to pass a new “Diversity, Equity, Inclusion and Social Justice”-themed class to earn a diploma.

The new college racial equity courses must, according to State University of New York documents:

  • Describe the historical and contemporary societal factors that shape the development of individual and group identity involving race, class and gender.
  • Analyze the role that complex networks of social structures and systems play in the creation and perpetuation of the dynamics of power, privilege, oppression and opportunity.
  • Apply the principles of rights, access, equity, and autonomous participation to past, current, or future social justice action.

While the primary focus is on equity and social justice in the US, courses can also look at what has happened or is currently happening in other countries for comparison, the mandate reads.

Critics say such mandated “equity” training actually flies in the face of goals for racial “equality.”

SUNY Suffolk Community College political science professor Nicholas Giordano slams the university's new racial equity curriculum and divisive.
SUNY Suffolk Community College political science professor Nicholas Giordano slams the university’s new racial equity curriculum as divisive.
Courtesy of Nicholas Giordano

“This is nuts,” Nicholas Giordano, a political science professor at SUNY’s Suffolk Community College told The Post. “SUNY is one of the best university systems in the country. Why are they doing this?!”

“DEISJ is a cultural movement, not based on academics. Unfortunately, SUNY responded to the mob.”

Giordano, a fellow at the conservative watchdog group Campus Reform, said the new DEISJ coursework seeks to portray the US as “inherently racist” and tries to undermine the American identity that unifies all citizens by “creating groups and pitting them against each other.”

He said the curriculum seeks to have students “defined by the color of their skin.”

“To tell [minority students] they can’t compete with a white person is insulting and racist.”

1of3
Incoming students at Fashion Institute of Technology will be required to take a new diversity and racial equity course to graduate, beginning in the fall.
Incoming freshmen students SUNY's flagship Stony Brook U. campus will have to pass a new diversity and equity course in order to graduate.
Incoming freshmen students at SUNY’s flagship Stony Brook U. campus will have to pass a new diversity and equity course in order to graduate.
Advertisement

State Conservative Party chairman Jerry Kassar said the new SUNY curriculum is reminiscent of the debate raging over whether “critical race theory” should be taught in the lower grades.

“This is a woke, left wing agenda. It’s disturbing. It’s dangerous,” Kassar said.

“They’re treating everybody as having prejudice. It’s like a socialist, communist state. It’s unbelievable. These ideas are best addressed at home.”

Several other campuses across the country — Drake University, Brandeis University, Villanova University and the University of California system among them — have imposed similar racial equity programs.

Incoming freshmen at SUNY campuses will be required to pass a certified DEISJ course to graduate.

The diversity and equity curriculum was approved by SUNY under former Gov. Andrew Cuomo's then hand-picked chancellor James Malatras, a former aide.
The diversity and equity curriculum was approved by SUNY under former Gov. Andrew Cuomo’s then hand-picked chancellor James Malatras, a former aide.
AP

SUNY’s Board of Trustees approved the sweeping 25-point “Diversity, Equity and Inclusion Act” plan aimed at closing “racial equity gaps” in February of 2021 — while New York was grappling with the once in a century coronavirus pandemic. It was crafted under former Gov. Andrew Cuomo and his hand-picked chancellor, James Malatras.

The press release then said the new policy called on campuses to “Embed Racial Equity into Curriculum and Toward Racial Equity.” The plan also includes updating the criminal justice curriculum.

SUNY Chancellor John King defended the public university's new Diversity, Inclusion, Equity and Social Justice curriculum as necessary in a modern society.
SUNY Chancellor John King defended the public university’s new “Diversity, Inclusion, Equity and Social Justice” curriculum as necessary in a modern society.
AP

SUNY Chancellor John King defended the new DEISJ curriculum and course work as broadening understanding and tolerance.

“Exposure to, and understanding of, diversity is essential to success in our modern society and economy. As a leader in preparing the future workforce and citizenry, SUNY is committed to embedding diversity into the foundation of all it does – from academics to campus life and everything in between,” said King, the former New York State Education commissioner.

“By recognizing and celebrating our diversity and fostering respectful dialogue and debate, SUNY provides students with the world-class education they deserve.”

The SUNY  Faculty Senate and Faculty Council of Community Colleges recently issued guidance on approving courses to comply with the new DEISJ requirement. 

“Since students need to complete courses prior to transfer or graduation, it is our recommendation that DEISJ content be housed in a single course,” the document says.The guidance says DEISJ will be embedded across many courses and programs and “most campuses will need to make significant changes to existing curriculum to have courses that fulfill the DEISJ learning outcomes.”

SUNY sources said officials consulted with faculty and students on campuses for months before approving the plan, and there’s a broad support for it.

https://nypost.com/2023/01/31/suny-makes-new-racial-equity-class-mandatory-for-graduation-at-all-schools/